A study on RGB-5088 for type 1 diabetes
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests a new treatment called RGB-5088 in people with type 1 diabetes. It aims to see if the treatment is safe and if it helps control blood sugar.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- You have type 1 diabetes (even if you have had an organ transplant like a liver or kidney).
- Your stimulated C-peptide level is less than 0.3 ng/mL (a test that shows how much insulin your body still makes).
- You have had at least one severe low blood sugar event in the past 12 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests a new experimental drug (NNC0487-0111) designed to help regulate insulin levels in adults with type 2 diabetes. Researchers want to see if it works safely and effectively when combined with your current diabetes medications.
This trial tests a new medication called BGM0504 for people with type 2 diabetes that is not well managed with diet and exercise alone. It aims to see if the drug can help lower blood sugar levels.
This study tests an experimental tablet to see if it can help control blood sugar in people with type 2 diabetes. It may be an option for those who are already on metformin or managing with diet and exercise.
This study tests a program to help people with type 1 diabetes improve their blood sugar control using continuous glucose monitors, insulin pumps, and education sessions. It includes remote monitoring and camp activities for some participants.
This trial tests a new continuous glucose monitor (CGM) designed to help manage blood sugar levels. You will wear the device for 15 days and attend three clinic visits to see how well it works.
This study tests a new medication, MTX228, to see if it can help people with type 1 diabetes who still make some insulin. It may slow the loss of your own insulin production and improve blood sugar control.
Hear when a new Diabetes Mellitus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.